Even though experimental insights are currently lacking in AML models, the combination of ferroptosis-inducing agents such as APR-246/eprenetapopt, which is promising in treating TP53-mutated AML [101,102], may benefit from the combination with ICB, as anti-CTLA4 or anti-PD(L)1 (Figure 1). This evidence concerns the gene CD274 and acute myeloid leukemia.